DF Dent & Co. Inc. Has $113.57 Million Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

DF Dent & Co. Inc. lessened its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 2.9% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 218,304 shares of the medical research company's stock after selling 6,475 shares during the quarter. Thermo Fisher Scientific makes up about 1.4% of DF Dent & Co. Inc.'s holdings, making the stock its 27th biggest holding. DF Dent & Co. Inc. owned 0.06% of Thermo Fisher Scientific worth $113,568,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Geode Capital Management LLC lifted its position in shares of Thermo Fisher Scientific by 1.7% during the 3rd quarter. Geode Capital Management LLC now owns 7,659,943 shares of the medical research company's stock worth $4,719,477,000 after purchasing an additional 127,564 shares during the last quarter. Coldstream Capital Management Inc. raised its stake in shares of Thermo Fisher Scientific by 11.4% in the third quarter. Coldstream Capital Management Inc. now owns 9,705 shares of the medical research company's stock valued at $5,972,000 after acquiring an additional 995 shares during the last quarter. Greenwood Gearhart Inc. lifted its position in Thermo Fisher Scientific by 9.8% during the 3rd quarter. Greenwood Gearhart Inc. now owns 20,579 shares of the medical research company's stock worth $12,730,000 after buying an additional 1,837 shares in the last quarter. Nordea Investment Management AB grew its stake in shares of Thermo Fisher Scientific by 23.6% during the fourth quarter. Nordea Investment Management AB now owns 55,452 shares of the medical research company's stock valued at $28,868,000 after purchasing an additional 10,606 shares during the last quarter. Finally, S.E.E.D. Planning Group LLC raised its position in shares of Thermo Fisher Scientific by 6.2% during the fourth quarter. S.E.E.D. Planning Group LLC now owns 10,626 shares of the medical research company's stock worth $5,528,000 after acquiring an additional 618 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company's stock.

Remove Ads

Analysts Set New Price Targets

A number of research firms recently weighed in on TMO. Wells Fargo & Company boosted their price target on shares of Thermo Fisher Scientific from $660.00 to $680.00 and gave the stock an "overweight" rating in a research note on Friday, January 31st. Royal Bank of Canada set a $693.00 target price on Thermo Fisher Scientific in a research note on Friday, January 31st. Scotiabank boosted their price objective on shares of Thermo Fisher Scientific from $605.00 to $650.00 and gave the company a "sector perform" rating in a report on Monday, February 3rd. UBS Group raised their price objective on Thermo Fisher Scientific from $700.00 to $715.00 and gave the stock a "buy" rating in a research note on Friday, January 31st. Finally, StockNews.com raised Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research report on Tuesday, January 14th. Four investment analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $653.23.

Insiders Place Their Bets

In other news, CFO Stephen Williamson sold 9,825 shares of the company's stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total transaction of $5,753,421.75. Following the completion of the transaction, the chief financial officer now directly owns 27,296 shares in the company, valued at approximately $15,984,264.64. This represents a 26.47 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the company's stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $516.67, for a total value of $5,166,700.00. Following the completion of the transaction, the chief executive officer now directly owns 115,174 shares of the company's stock, valued at approximately $59,506,950.58. The trade was a 7.99 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 23,900 shares of company stock worth $13,106,062 in the last quarter. Corporate insiders own 0.34% of the company's stock.

Thermo Fisher Scientific Stock Performance

TMO stock traded down $0.81 during mid-day trading on Tuesday, hitting $437.06. 1,297,758 shares of the company were exchanged, compared to its average volume of 1,654,164. Thermo Fisher Scientific Inc. has a 1-year low of $411.21 and a 1-year high of $627.88. The business has a 50 day simple moving average of $529.09 and a 200-day simple moving average of $545.75. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. The stock has a market capitalization of $164.89 billion, a PE ratio of 26.37, a price-to-earnings-growth ratio of 2.99 and a beta of 0.86.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. On average, equities analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 15th. Shareholders of record on Friday, March 14th will be paid a $0.43 dividend. This is a boost from Thermo Fisher Scientific's previous quarterly dividend of $0.39. The ex-dividend date of this dividend is Friday, March 14th. This represents a $1.72 annualized dividend and a yield of 0.39%. Thermo Fisher Scientific's payout ratio is 10.41%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.